Toulouse and Geneva, December 22, 2016
Genticel and Genkyotex Announce Intention to Enter into Strategic Combination. Genkyotex is a pioneer in discovery and development of NOX therapeutics.
Transaction would create a European group with a pipeline of first-in-class NOX inhibitors in fibrosis and inflammatory pain. Execution of a contribution agreement for 100% of Genkyotex’s shares and issuance of new Genticel shares in remuneration thereof . Transaction is subject to Genticel shareholders’ approval during a general meeting to be held in Q1 2017.
Further information at :